PSI-6130

Last updated
PSI-6130
PSI-6130.svg
Clinical data
ATC code
  • none
Identifiers
  • 4-Amino-1-((2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C10H14FN3O4
Molar mass 259.237 g·mol−1
3D model (JSmol)
  • C[C@]1([C@@H]([C@H](O[C@H]1n2ccc(nc2=O)N)CO)O)F
  • InChI=1S/C10H14FN3O4/c1-10(11)7(16)5(4-15)18-8(10)14-3-2-6(12)13-9(14)17/h2-3,5,7-8,15-16H,4H2,1H3,(H2,12,13,17)/t5-,7-,8-,10-/m1/s1
  • Key:NYPIRLYMDJMKGW-VPCXQMTMSA-N
   (verify)

PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark. [1] Specifically, PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called NS5B. [2]

PSI-6130 is currently being developed by Hoffmann–La Roche as a 3',5'-diisobutyrl ester prodrug, R7128. [3] R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1. [4]

References

  1. ↑ Clark JL, Hollecker L, Mason JC, Stuyver LJ, Tharnish PM, Lostia S, et al. (August 2005). "Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication". Journal of Medicinal Chemistry. 48 (17): 5504–8. doi:10.1021/jm0502788. PMID   16107149.
  2. ↑ Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, et al. (2006). "Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication". Antiviral Chemistry & Chemotherapy. 17 (2): 79–87. doi:10.1177/095632020601700203. PMID   17042329. S2CID   22710780.
  3. ↑ Cole P, Castaner R, Bolos J (2009). "R-7128: RNA-directed RNA polymerase (NS5B) inhibitor treatment of hepatitis C virus infection" . Drugs of the Future. 34 (4): 282–290. doi:10.1358/dof.2009.034.04.1367744.
  4. ↑ Gane EJ, Roberts SK, Stedman CA, Angus PW, Ritchie B, Elston R, et al. (October 2010). "Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial". Lancet. 376 (9751): 1467–75. doi:10.1016/S0140-6736(10)61384-0. PMID   20951424. S2CID   28977802.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.